Smith+Nephew Inks Deal for Breakthrough Pelvic Fracture Technology

LONDON, UK – February 23, 2026 – Global medical technology giant Smith+Nephew has announced a significant distribution agreement with SI-BONE, a leader in procedural solutions for compromised bone. The deal centers on SI-BONE's innovative iFuse TORQ portfolio, a move set to bolster Smith+Nephew’s offerings for pelvic fracture fixation and strengthen its foothold in the high-stakes orthopedic trauma market.

The partnership grants Smith+Nephew distribution rights to a technology that has already gained recognition for its potential to transform patient outcomes, particularly for complex and often debilitating pelvic injuries. By integrating SI-BONE’s specialized implants into its extensive commercial platform, Smith+Nephew aims to accelerate the adoption of a new standard of care for surgeons and patients alike.

“We’re incredibly excited to partner with SI-BONE,” said Scott Gunn, Vice President Trauma, Extremities and Shoulder at Smith+Nephew, in a statement. “This collaboration reflects a shared commitment to innovation, clinical excellence, and improving patient outcomes. By combining SI-BONE’s industry leadership with Smith+Nephew’s established commercial platform, we see a meaningful opportunity to expand access to differentiated solutions, deepen surgeon engagement, and drive sustainable growth.”

Advancing Care Beyond Traditional Methods

At the heart of the agreement is the iFuse TORQ TNT implant system. For decades, surgeons have relied on traditional cannulated screws for pelvic fracture fixation—a technology originally designed for other parts of the body. These legacy screws can be inadequate for the unique anatomical stresses and often poor bone quality found in the pelvis, especially in elderly patients suffering from fragility fractures. This can lead to complications such as screw loosening, persistent pain, and the need for revision surgeries.

The iFuse TORQ TNT system was engineered specifically to overcome these challenges. Its 3D-printed, porous titanium surface is designed for osseointegration, encouraging the patient's bone to grow into the implant for a more stable, long-term fixation. The system's design is optimized for the anatomy of the sacrum and ilium, providing enhanced stability that may allow for earlier patient mobilization and recovery.

This innovative approach earned the iFuse TORQ TNT system a Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA). This status is reserved for technologies that have the potential to provide more effective treatment for life-threatening or irreversibly debilitating conditions compared to existing options. For orthopedic surgeons, this designation signals a significant leap forward.

“The streamlined instrumentation and implant design provide excellent fixation, allowing for quick and precise implantation,” noted one orthopedic surgeon familiar with the technology. This efficiency is critical for patients with fragile bones, leading to reduced operating time, minimized risks, and the potential for better long-term outcomes, especially for osteoporotic patients.

The Reimbursement Catalyst Driving Adoption

A critical factor fueling the optimism around this partnership is not just clinical but also economic. The iFuse TORQ TNT system is eligible for a Medicare New Technology Add-on Payment (NTAP), a powerful incentive designed to accelerate the adoption of groundbreaking medical devices within the U.S. healthcare system.

The NTAP program provides hospitals with additional reimbursement—up to $4,136 per procedure in this case—above the standard Medicare payment when they use qualifying new technologies. This addresses a common barrier to innovation: the higher upfront cost of advanced devices. By mitigating the financial burden on hospitals, the NTAP encourages providers to choose the most clinically effective option for their patients, rather than being limited by budget constraints.

This reimbursement pathway is a game-changer. It not only validates the clinical novelty and substantial benefit of the iFuse TORQ TNT system but also provides a clear financial runway for its widespread use. For Smith+Nephew, this de-risks the commercialization process and provides its sales force with a powerful argument for why hospitals should stock and use the new implants. The policy effectively aligns financial incentives with the pursuit of better patient outcomes, creating a favorable environment for this technology to thrive.

A Strategic Alliance to Reshape the Trauma Market

The agreement is a calculated strategic maneuver for both companies, positioning them to capitalize on a rapidly growing market. The global market for pelvic fixation systems is valued at over $1 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of over 7%. The sacroiliac (SI) joint fusion market, also addressed by the iFuse portfolio, is growing even faster, with some analysts projecting a CAGR of nearly 20%.

For Smith+Nephew, this deal aligns perfectly with its overarching strategy to drive growth through innovation and portfolio optimization. After a period of focusing on its internal "12-Point Plan" to improve performance, the company is leveraging its strengthened commercial engine to bring in best-in-class external technologies. The addition of the iFuse TORQ portfolio immediately enhances its Trauma and Extremities division, giving it a differentiated product in a high-need area dominated by competitors like Stryker and DePuy Synthes.

For SI-BONE, a pioneer in the SI joint fusion space, the partnership is transformative. While the company possesses leading-edge technology and a strong clinical evidence base, it lacks the global commercial footprint of a behemoth like Smith+Nephew. This agreement provides immediate access to an established, worldwide sales channel, dramatically expanding its market reach and potential for revenue growth.

The collaboration represents a classic win-win synergy: SI-BONE's clinical innovation is paired with Smith+Nephew's commercial power. As the healthcare landscape continues to evolve, this combination of breakthrough technology, strategic distribution, and supportive reimbursement policy provides a potent formula for addressing unmet clinical needs and capturing significant market share in the demanding field of orthopedic trauma.